STANDRING, DAVID,SOMMADOSSI, JEAN-PIERRE,PATTY, APRIL L.,SEIFER, MARIA
申请号：
CA2498731
公开号：
CA2498731C
申请日:
2003.09.15
申请国别(地区):
CA
年份:
2012
代理人:
摘要：
It has been discovered that .szlig.-L-2'-deoxynucleosides are active againstdrug~resistant hepatitis B virus with mutations. A method for treatinglamivudine resistant HBV (M552V) in a host is provided that includesadministering a .szlig.-L-2'~deoxynucleoside or its pharmaceuticallyacceptable salt, ester or prodrug. In addition, a method for preventinglamivudine resistant HBV (M552V) mutation from occurring in a naïve host isprovided that includes administering a .szlig.-L-2'-deoxynucleoside or itspharmaceutically acceptable salt, ester or prodrug. A method for preventingand/or suppressing the emergence of the HBV double mutant (L528M/M552V) in ahost is also provided that includes administering a (3-L-2'-deoxynucleoside orits pharmaceutically acceptable salt, ester or prodrug.
